Key result
Selexipag significantly improved right ventricular systolic pressure and right ventricular hypertrophy, attenuated occlusive vascular lesions, and reduced mortality in rat models of severe pulmonary arterial hypertension.
Why the study?
The pharmacological effects of prostacyclin and its analogs on occlusive vascular remodeling in pulmonary arterial hypertension have not been elucidated.
Does selexipag improve pulmonary hemodynamics and vascular remodeling in rat models of severe PAH?
Does selexipag improve pulmonary hemodynamics and vascular remodeling in rat models of severe PAH?
Absolute Event Rate: 0% vs 70%
p-value: p=<0.01
Selexipag ameliorates pulmonary hemodynamics, vascular remodeling, and mortality in severe rat models of PAH, supporting its clinical efficacy.
Selexipag may attenuate occlusive remodeling in severe PAH models; leaves open whether benefits extend beyond vasodilation in patients.
Pulmonary arterial hypertension (PAH) is a lethal disease characterized by a progressive increase in pulmonary artery pressure due to an increase in vessel tone and occlusion of vessels. The endogenous vasodilator prostacyclin and its analogs are used as therapeutic agents for PAH. However, their pharmacological effects on occlusive vascular remodeling have not been elucidated yet. Selexipag is a recently approved, orally available and selective prostacyclin receptor agonist with a non-prostanoid structure. In this study, we investigated the pharmacological effects of selexipag on the pathology of chronic severe PAH in Sprague-Dawley and Fischer rat models in which PAH was induced by a combination of injection with the vascular endothelial growth factor receptor antagonist Sugen 5416 and exposure to hypoxia (SuHx). Oral administration of selexipag for three weeks significantly improved right ventricular systolic pressure and right ventricular (RV) hypertrophy in Sprague-Dawley SuHx rats. Selexipag attenuated the proportion of lung vessels with occlusive lesions and the medial wall thickness of lung arteries, corresponding to decreased numbers of Ki-67-positive cells and a reduced expression of collagen type 1 in remodeled vessels. Administration of selexipag to Fischer rats with SuHx-induced PAH reduced RV hypertrophy and mortality caused by RV failure. These effects were probably based on the potent prostacyclin receptor agonistic effect of selexipag on pulmonary vessels. Selexipag has been approved and is used in the clinical treatment of PAH worldwide. It is thought that these beneficial effects of prostacyclin receptor agonists on multiple aspects of PAH pathology contribute to the clinical outcomes in patients with PAH.
No takes yet. Share an insight, caveat, or question.
Honda et al. (2020) studied Pulmonary arterial hypertension. Selexipag vs. Vehicle (0.5% methylcellulose) was evaluated on Mortality (Fischer rats) (p=<0.01). Selexipag significantly improved right ventricular systolic pressure and right ventricular hypertrophy, attenuated occlusive vascular lesions, and reduced mortality in rat models of severe pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: